000424

events. Implications for prevention / D.W. Bates [et al.] // JAMA, 1995, 274, 29-34. 158. Inman, W.H.W. Requirements for risk benefit assessment of drugs before withdrawal / W.H.W. Inman // B.I.R.A. J., 1986, 5 (2), 11-15. 159. Kubota, K. Prescription-event monitoring in Japan (J-PEM) / K. Kubota // Drug Saf. 2002, 25(6), 441-444. 160. Lazarou, J. Incidence of adverse drug reactions in hospitalized patients / J.Lazarou, B.H.Pomeranz, P.N. Corey //JAMA, 1998; №279:1200­ 1205. 161. Leape, L.L. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II, N. / L.L. Leape, T.A. Brennan, N. Laird // Engl. J. Med., 1991, 324, 377-384. 162. Lepori, V. Adverse internal medicine drug effects at hospital admission / V. Lepori, A. Perren, C. Marone // Schweiz Med Wochenschr, 1999, 19, 129 (24), 915-922. 163. Lindquist, R. Understanding and preventing adverse drug events / R. Lindquist, L.M. Gersema // AACN Clin. Issues, 1998, 9(1), 119-128. 164. Lindquist, R. Understanding and preventing adverse drug events, AACN / R. Lindquist, L.M. Gersema // Clin. Issues, 1998, 9(1), 119-128. 165. McBride, W.G. Thalidomide and congenital abnormalities / W.G. McBride // Lancet, 1961. - N 2. - p.1358. 166. Medication Errors at the Administration Stage in an Intensive Care Unit / E. Tissot [et al.] // Intensive Care. Med., 1999, 25(4), 353-359. 167. Medication errors in a pediatric department / Olsen P.M. [et al.]. Ugeskr Laeger, 1997, 14, 159(16), 2392-2395. 168. Moore, N.D. Serious ADR in a department of internal medicine / N.D. Moore, D. Lecaintre, C. Nobet // Pharmacoepidemiology and Drug Safety, 1995, 4, 74. 169. Newby, D. An introduction to ADRs / D. Newby // Curr. Therap., - 195 - 195